ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Acadia Pharma (ACAD) Misses Q1 EPS by 9c
May 7, 2020 4:44 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $90.1 million versus the consensus estimate of $91.51 million.
ACADIA entered 2020 with positive momentum. Successful execution of our commercial efforts led to continued strong... More
